What is Pathmaker Neurosystems?
Pathmaker Neurosystems is a clinical-stage company dedicated to pioneering non-invasive neuromodulation devices for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other severe neurological conditions. The company's core technology centers on multi-site direct current stimulation, designed to suppress neuronal hyperexcitability and promote protein degradation pathways. By aiming to restore damaged neural pathways and mitigate protein aggregation in motor neurons, Pathmaker Neurosystems is advancing a novel therapeutic approach, supported by robust pre-clinical and clinical research, to address unmet needs in neurodegenerative disease treatment.
How much funding has Pathmaker Neurosystems raised?
Pathmaker Neurosystems has raised a total of $2.2M across 2 funding rounds:
Debt
$36K
Other Financing Round
$2.2M
Debt (2021): $36K with participation from PPP
Other Financing Round (2024): $2.2M, investors not publicly disclosed
Key Investors in Pathmaker Neurosystems
PPP
Public-Private Partnership
What's next for Pathmaker Neurosystems?
The recent major strategic investment signals a pivotal moment for Pathmaker Neurosystems, likely enabling the acceleration of its product commercialization efforts and further clinical development. This capital infusion is expected to fuel the company's expansion into broader markets and support the scaling of its innovative neuromodulation technologies. The enterprise-level funding context suggests a focus on achieving significant milestones in regulatory approval and market penetration for its ALS and neurological disorder treatments.
See full Pathmaker Neurosystems company page
